BRPI0910456A2 - petídeos imunogênicos priônicos e suas repetições - Google Patents

petídeos imunogênicos priônicos e suas repetições

Info

Publication number
BRPI0910456A2
BRPI0910456A2 BRPI0910456A BRPI0910456A BRPI0910456A2 BR PI0910456 A2 BRPI0910456 A2 BR PI0910456A2 BR PI0910456 A BRPI0910456 A BR PI0910456A BR PI0910456 A BRPI0910456 A BR PI0910456A BR PI0910456 A2 BRPI0910456 A2 BR PI0910456A2
Authority
BR
Brazil
Prior art keywords
petids
prion
repetitions
immunogenic
prion immunogenic
Prior art date
Application number
BRPI0910456A
Other languages
English (en)
Inventor
Andrew Potter
Avijit Chakrabartty
Lorne Babiuk
Neil Cashman
Peter Hedlin
Philip Griebel
Scott Napper
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Publication of BRPI0910456A2 publication Critical patent/BRPI0910456A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2872—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910456A 2008-04-25 2009-04-23 petídeos imunogênicos priônicos e suas repetições BRPI0910456A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12550708P 2008-04-25 2008-04-25
PCT/IB2009/005890 WO2009130612A2 (en) 2008-04-25 2009-04-23 Prion epitopes and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0910456A2 true BRPI0910456A2 (pt) 2016-07-19

Family

ID=41217203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910456A BRPI0910456A2 (pt) 2008-04-25 2009-04-23 petídeos imunogênicos priônicos e suas repetições

Country Status (6)

Country Link
US (2) US9056918B2 (pt)
EP (1) EP2279203B1 (pt)
AU (1) AU2009239651B2 (pt)
BR (1) BRPI0910456A2 (pt)
CA (1) CA2721833A1 (pt)
WO (1) WO2009130612A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279203B1 (en) * 2008-04-25 2016-06-15 University Of Saskatchewan Prion epitopes and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859595A (en) 1985-05-03 1989-08-22 Strosberg Arthur D Method for preparing rabbit monoclonal antibodies, the cell lines used therein and the antibodies produced thereby
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US20030091579A1 (en) * 1998-05-05 2003-05-15 Jack G. Manns Methods of raising animals for meat production
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
EP1194164B8 (en) 1999-06-23 2007-03-21 IDEXX Laboratories Inc Prion protein peptides and uses thereof
DE60121729T2 (de) * 2001-04-19 2007-11-29 Dr. Hermann Schätzl Prion Proteindimere für Impfungen
EP1442300A2 (en) 2001-11-09 2004-08-04 King's College London Diagnosis demyelinating or spongiform disease
AU2003226513A1 (en) 2002-03-20 2003-10-08 Health Protection Agency Antibody that binds to a dimer of a prion protein for the treatment of TSE infection
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
US20050255525A1 (en) * 2004-05-13 2005-11-17 Bastian Frank O Safe method for isolation of prion protein and diagnosis of transmissible spongiform encephalopathies
WO2009015091A1 (en) * 2007-07-20 2009-01-29 The Government of the United States of America as represented by the Secretary of the Detection of infectious prion protein by seeded conversion of recombinant prion protein
EP2279203B1 (en) * 2008-04-25 2016-06-15 University Of Saskatchewan Prion epitopes and methods of use thereof

Also Published As

Publication number Publication date
EP2279203B1 (en) 2016-06-15
AU2009239651B2 (en) 2013-12-12
WO2009130612A3 (en) 2010-01-21
EP2279203A2 (en) 2011-02-02
WO2009130612A2 (en) 2009-10-29
US20090280125A1 (en) 2009-11-12
US9056918B2 (en) 2015-06-16
US20150313976A1 (en) 2015-11-05
AU2009239651A1 (en) 2009-10-29
CA2721833A1 (en) 2009-10-29
EP2279203A4 (en) 2011-08-31
US9376476B2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK2437790T3 (da) Konjugeringsfremgangsmåder
BRPI0907890A2 (pt) Implantes lacrimais e métodos relacionados
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI0918249A2 (pt) prótese
DE112009000964A5 (de) Tampon
SMT201500273B (it) Diidroetorfine e loro preparazione
FR2947556B1 (fr) Composition polyamide modifiee
DE112009003312A5 (de) Implantat
DK2307389T3 (da) Dibenzothiazepinderivat og anvendelser deraf
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
BRPI0910456A2 (pt) petídeos imunogênicos priônicos e suas repetições
BRPI0922008A2 (pt) compostos e respectivos metodos de preparação
FR2937843B1 (fr) Paravent medical
DE602009000508D1 (de) Implantat
FI20096360A0 (fi) Bioliima ja puulevy
ES1069883Y (es) Monolito publicitario
DOS2008000043S (es) Muñequera
UA17401S (uk) Вивіска
UA17469S (uk) Вивіска
UA18685S (uk) Вивіска
UA17910S (uk) Вивіска

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)